Randomized Trials Stopped Early : Systematic Review

Randomized Trials Stopped Early for Benefit A Systematic Review

Victor M. Montori, MD, MSc; P. J. Devereaux, MD; Neill K. J. Adhikari, MD; Karen E. A. Burns, MD; Christoph H. Eggert, MD; Matthias Briel, MD; Christina Lacchetti, MHSc; Teresa W. Leung, BHSc; Elizabeth Darling, RM, BHSc; Dianne M. Bryant, PhD; Heiner C. Bucher, MD, MPH; Holger J. Schünemann, MD, PhD; Maureen O. Meade, MD, MSc; Deborah J. Cook, MD, MSc; Patricia J. Erwin, MLS; Amit Sood, MD; Richa Sood, MD; Benjamin Lo, MD; Carly A. Thompson, BHSc; Qi Zhou, PhD; Edward Mills, PhD; Gordon H. Guyatt, MD, MSc


Randomized clinical trials (RCTs) that stop earlier than planned because of apparent benefit often receive great attention and affect clinical practice.

Their prevalence, the magnitude and plausibility of their treatment effects, and the extent to which they report information about how investigators decided to stop early are, however, unknown.


To evaluate the epidemiology and reporting quality of RCTs involving interventions stopped early for benefit.

Data Sources

Systematic review up to November 2004 of MEDLINE, EMBASE, Current Contents, and full-text journal content databases to identify RCTs stopped early for benefit.

Study Selection

Randomized clinical trials of any intervention reported as having stopped early because of results favoring the intervention. There were no exclusion criteria.

Data Extraction

Twelve reviewers working independently and in duplicate abstracted data on content area and type of intervention tested, reporting of funding, type of end point driving study termination, treatment effect, length of follow-up, estimated sample size and total sample studied, role of a data and safety monitoring board in stopping the study, number of interim analyses planned and conducted, and existence and type of monitoring methods, statistical boundaries, and adjustment procedures for interim analyses and early stopping.

Data Synthesis Of 143 RCTs stopped early for benefit, the majority (92) were published in 5 high-impact medical journals. Typically, these were industry-funded drug trials in cardiology, cancer, and human immunodeficiency virus/AIDS. The proportion of all RCTs published in high-impact journals that were stopped early for benefit increased from 0.5% in 1990-1994 to 1.2% in 2000-2004 (P<.001 for trend).

On average, RCTs recruited 63% (SD, 25%) of the planned sample and stopped after a median of 13 (interquartile range [IQR], 3-25) months of follow-up, 1 interim analysis, and when a median of 66 (IQR, 23-195) patients had experienced the end point driving study termination (event).

The median risk ratio among truncated RCTs was 0.53 (IQR, 0.28-0.66). One hundred thirty-five (94%) of the 143 RCTs did not report at least 1 of the following: the planned sample size (n = 28), the interim analysis after which the trial was stopped (n = 45), whether a stopping rule informed the decision (n = 48), or an adjusted analysis accounting for interim monitoring and truncation (n = 129).

Trials with fewer events yielded greater treatment effects (odds ratio, 28; 95% confidence interval, 11-73).

Conclusions RCTs stopped early for benefit are becoming more common, often fail to adequately report relevant information about the decision to stop early, and show implausibly large treatment effects, particularly when the number of events is small.

These findings suggest clinicians should view the results of such trials with skepticism.

Author Affiliations: Department of Clinical Epidemiology and Biostatistics (Drs Montori, Devereaux, Adhikari, Burns, Bryant, Schünemann, Meade, Cook, Zhou, Mills, and Guyatt and Ms Lacchetti and Darling), Bachelor of Health Sciences Programme (Mss Leung and Thompson), and Department of Medicine (Drs Devereaux, Mead, Cook, Lo, and Guyatt), McMaster University, Hamilton, Ontario; Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Drs Montori, Eggert, A. Sood, and R. Sood and Ms Erwin); Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario (Drs Adhikari and Burns); Basel Institute for Clinical Epidemiology, University Hospital, Basel, Switzerland (Drs Briel and Bucher); and Departments of Medicine and Social and Preventive Medicine, University at Buffalo, Buffalo, NY and Division of Clinical Research Development and INFORMAtion Translation, Italian National Cancer Institute Regina Elena, Rome, Italy (Dr Schünemann).

JAMA. 2005;294:2203-2209.

Vol. 294 No. 17, November 2, 2005

ASCO - Ethical/Clinical Dilemmas After Early Closure

LINK to ASCO educational session in 2005 AM Soc for Clinical Oncology

Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.